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Abstract
Background
The link between DNA methylation, obesity, and adiposity-related diseases in the general
population remains uncertain.
Methods and Findings
We conducted an association study of body mass index (BMI) and differential methylation
for over 400,000 CpGs assayed by microarray in whole-blood-derived DNA from 3,743 par-
ticipants in the Framingham Heart Study and the Lothian Birth Cohorts, with independent
replication in three external cohorts of 4,055 participants. We examined variations in whole
blood gene expression and conducted Mendelian randomization analyses to investigate the
functional and clinical relevance of the findings. We identified novel and previously reported
BMI-related differential methylation at 83 CpGs that replicated across cohorts; BMI-related
differential methylation was associated with concurrent changes in the expression of genes
in lipid metabolism pathways. Genetic instrumental variable analysis of alterations in methyl-
ation at one of the 83 replicated CpGs, cg11024682 (intronic to sterol regulatory element
binding transcription factor 1 [SREBF1]), demonstrated links to BMI, adiposity-related traits,
and coronary artery disease. Independent genetic instruments for expression of SREBF1
supported the findings linking methylation to adiposity and cardiometabolic disease. Methyl-
ation at a substantial proportion (16 of 83) of the identified loci was found to be secondary to
differences in BMI. However, the cross-sectional nature of the data limits definitive causal
determination.
Conclusions
We present robust associations of BMI with differential DNA methylation at numerous loci in
blood cells. BMI-related DNA methylation and gene expression provide mechanistic insights
into the relationship between DNA methylation, obesity, and adiposity-related diseases.
Author Summary
Why Was This Study Done?
• Genetic sequence variants explain only a modest proportion of the variation in body
mass index (BMI) and cardiometabolic disease in the general population.
• There is limited understanding of the link of DNA methylation—a well-characterized epi-
genetic modification—with BMI and cardiometabolic disease in the general population.
Methylome-Wide Study of BMI
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are available at dbGaP under the accession number
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data are available at dbGaP under the accession
number phs000821.v1.p1.
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What Did the Researchers Do and Find?
• We conducted a cross-sectional analysis of the association of BMI with leukocyte DNA
methylation at over 400,000 sites in the genome among 7,798 community-dwelling
adults.
• We identified associations between BMI and methylation at 83 replicated sites (includ-
ing 50 novel sites) and concurrent differences in expression in whole blood of genes
overrepresented in lipid metabolism pathways.
• Using genetic sequence variants to model exposure to differential DNA methylation
and tissue-specific gene expression, we found differential methylation and expression of
SREBF1 to be implicated in BMI, adiposity-related traits, and coronary artery disease.
• Using genetic sequence variants to model exposure to differences in BMI, we found a
substantial proportion of the differentially methylated sites (16 of 83) to be downstream
of BMI.
What Do These Findings Mean?
• Evidence is accumulating that epigenetic modifications, such as DNA methylation, are
related to obesity-related diseases in the general population.
• We provide support for a role of genomic regulation of a lipid metabolism transcription
factor, SREBF1, in adiposity and coronary artery disease.
• Mendelian randomization approaches can help prioritize relevant loci for future func-
tional studies, but the cross-sectional observational nature of our study limits definitive
causal inference.
Introduction
Obesity is highly prevalent in developed nations [1] and contributes to a substantial burden of
morbidity and mortality [2,3]. Despite advances in the understanding of genetic variants, life-
style factors, and gene–environment interactions associated with obesity [4–7], much of the
interindividual variation in body weight remains unexplained by measurable lifestyle and
genetic factors. DNA methylation, one of the most frequent and well-characterized epigenetic
modifications, reflects at the molecular level a wide range of environmental exposures and
genetic influences [8]. By stabilizing chromatin structure and altering gene expression, DNA
methylation has the potential to affect an individual’s susceptibility to obesity (see review in
[9]). Further, changes in the methylation of DNA may occur secondarily to obesity and may
consequently influence the development of adiposity-related diseases such as diabetes, dyslipi-
demia, hypertension, and cardiovascular disease. Large gaps in knowledge remain as to how
human epigenetic modifications relate to obesity and its sequelae.
Epigenetic biomarkers represent a largely untapped precision medicine resource to guide
therapy decisions using an individual’s epigenetic profile obtained from blood samples [10].
Methylome-Wide Study of BMI
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Identification of clinically relevant epigenetic loci in blood holds the potential to create a foun-
dation upon which to base future functional studies and trials to test epigenetically guided clin-
ical decision making for cardiometabolic diseases. In addition, we may gain novel insights into
the molecular underpinnings of obesity and adiposity-related diseases through the study of dif-
ferentially methylated DNA loci in blood. Doing so may lead to the identification of biologi-
cally relevant therapeutic targets.
The present study provides results of an epigenome-wide association study (EWAS) of
body mass index (BMI) in over 3,700 participants from the Framingham Heart Study (FHS)
and the Lothian Birth Cohorts (LBCs) of 1921 and 1936 (LBC1921 and LBC1936). We con-
ducted independent external replication in over 4,000 individuals from the Atherosclerosis
Risk in Communities (ARIC), Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN), and Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS)
cohort studies. We examined the functional relevance of the identified loci by interrogating
the known trans-tissue regulatory functions and concomitant changes in gene expression in
blood. In addition, we explored the clinical relevance of the findings for adiposity-related dis-
eases with genetic instrumental variable (IV) analyses using bidirectional and two-step trans-
tissue Mendelian randomization (MR) approaches [11–13].
Methods
Study Design
The study includes two major components. First, we conducted an EWAS of BMI. Second,
BMI-related differentially methylated loci were taken forward for further analyses to better
understand the magnitude of association, regulatory annotation, functional implications, and
clinical relevance (Fig 1). The discovery/replication design and secondary models for the BMI
EWAS were defined a priori (S1 Text). Downstream analyses to characterize the discovered
loci were outlined a priori, but the final approach was primarily driven by the findings and
concurrent advancements in the field.
Ethics
The FHS protocols and participant consent forms were approved by the institutional
review board of Boston University School of Medicine. Ethics permission for the LBC1921 was
obtained from the Lothian Research Ethics Committee (Wave 1: LREC/1998/4/183). Ethics
permission for the LBC1936 was obtained from the Multi-Centre Research Ethics Committee
for Scotland (Wave 1: MREC/01/0/56) and the Lothian Research Ethics Committee (Wave 1:
LREC/2003/2/29). Written informed consent was obtained from all discovery cohort (FHS
and LBC) and replication cohort (ARIC, GOLDN, and PIVUS) participants.
Study Participants
Data for the discovery phase of this investigation were drawn from the FHS offspring cohort
[14] and the LBCs of 1921 and 1936 [15–17]. As previously described [14], the FHS off-
spring cohort was initially recruited in 1971 and included 5,124 offspring (and their
spouses) from the FHS original cohort [18]. The eligible sample for this investigation was
from the 3,021 participants in the FHS offspring cohort who attended the eighth examina-
tion cycle from 2005 to 2008. The LBC1921 and LBC1936 samples derive from the Scottish
Mental Surveys of 1932 and 1947, respectively, when nearly all 11-y-old children in Scotland
completed an IQ-type test in school. The LBC studies provided follow-up of surviving par-
ticipants, most of whom were living in the Lothian region (Edinburgh city and outskirts)
Methylome-Wide Study of BMI
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of Scotland. The current study draws upon the older-age baseline examinations of 551 par-
ticipants in LBC1921 recruited in 1999–2001 and 1,091 participants in LBC1936 recruited
in 2004–2007.
Anthropometric Measurements
Height and weight were measured in each study using established protocols as described in
detail in the S1 Methods. BMI was calculated as weight (in kilograms) divided by height (in
meters) squared.
Fig 1. Series of analyses conducted for the epigenome-wide association study of body mass index. ARIC, Atherosclerosis Risk in
Communities; BMI, body mass index; DHS, DNase I hypersensitive site; FHS, Framingham Heart Study; GO, Gene Ontology; GOLDN,
Genetics of Lipid Lowering Drugs and Diet Network; GWAS, genome-wide association study; LBC, Lothian Birth Cohorts; MR, Mendelian
randomization; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; TSS, transcription start site.
doi:10.1371/journal.pmed.1002215.g001
Methylome-Wide Study of BMI
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Molecular Genomics
DNA from whole blood samples was collected at the same examination assessment as the
anthropometric and covariate measurements in both studies. DNA methylation, assayed with
the Infinium HumanMethylation450 BeadChip [19] (Illumina), was available for 2,846 FHS
participants and 1,518 LBC participants (514 from LBC1921 and 1,004 from LBC1936). Details
of rigorous quality control, normalization procedures, and exclusions of non-autosomal
probes, cross-hybridizing probes, and probes with underlying single nucleotide polymor-
phisms (SNPs) are described in S1 Methods. Each discovery and replication cohort conducted
cohort-specific preprocessing pipelines that allowed each cohort to address study-specific tech-
nical and batch effects. This design allowed for the selection of true biological signals indepen-
dent of bias introduced from uniform processing methods. After quality control in the
discovery cohorts, there were 402,358 shared CpG (cytosine-phosphate-guanine) methylation
probes available for analyses in 2,377 FHS and 1,366 LBC participants (446 from LBC1921 and
920 from LBC1936). Final sample size was determined by the number of community-based
participants in the discovery cohorts who consented to genomic studies and who had available
DNA and methylation assays passing quality control measures. In the FHS, SNP data were
obtained from the Affymetrix 550K Array imputed to the 1000 Genomes Project reference
panel, as previously reported [20]. The LBC samples were genotyped using the Illumina
Human610-Quad v1.0 genotyping platform and imputed to the 1000 Genomes Project refer-
ence panel as well. Gene expression in blood was available in the FHS and was measured using
the Affymetrix Human Exon 1.0 ST GeneChip as described in S1 Methods.
Epigenome-Wide Association Study of BMI
In the FHS, linear mixed effects regression models were conducted to test the association
between site-specific DNA methylation and BMI. The primary model was adjusted for age,
sex, family relatedness (random effect), and surrogate variables (to account for differential cell
proportions and technical effects) [21], with BMI as the independent variable of interest and
DNA methylation (inverse-normal transformed) as the dependent variable. In the LBC, linear
regression models were conducted adjusting for age, sex, and white blood cell counts, with
each DNA methylation probe (residual taken forward from a generalized linear model with a
logistic link function adjusting for technical and batch effects) as the dependent variable and
BMI as the independent variable of interest. Further analytical details for the discovery cohorts
are described in S1 Methods. In both cohorts, secondary models were conducted: (1) addition-
ally adjusting for smoking status, (2) restricted to participants with BMI 18–35 kg/m2 in order
to avoid confounding due to frailty or morbid obesity and obesity-related diseases, and (3)
testing for age and sex interactions. Results from the FHS and LBCs were meta-analyzed using
methods that weighted the p-value by sample size [22]. Directional consistency of statistically
significant cohort-specific effects was confirmed for all methylome-wide significant findings
from the discovery meta-analysis. We focused our analyses on the resultant test statistic and
direction of effect from the independent variable of interest (BMI) as the cohort-specific linear
regression coefficients were not directly comparable due to the differences in the preprocessing
approach between cohorts. The threshold for statistical significance in the discovery phase was
defined by Bonferroni correction for multiple testing to be 0.05/405,000 (p-value< 1.2 × 10−7).
A flowchart of analyses conducted is presented in Fig 1.
External Replication of EWAS Findings
The methylome-wide significant CpGs from the FHS and LBC meta-analysis were taken for-
ward to external replication in three independent cohorts that used the same methylation
Methylome-Wide Study of BMI
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microarray: the ARIC study, using whole-blood-derived DNA from 2,096 participants of Afri-
can ancestry; the GOLDN study, using DNA derived from CD4+ cells from 992 participants of
European ancestry; and the PIVUS study, using whole blood-derived DNA from 967 partici-
pants of Swedish ancestry. Description and analytical methods of the replication cohorts are
supplied in S1 Methods. Replication cohorts also conducted cohort-specific preprocessing.
Replication was examined within each cohort individually and then in a meta-analysis of all
three replication cohorts (using p-value-weighted methods and ensuring directional consis-
tency as described above). The threshold for statistically significant replication was determined
by Bonferroni correction to be 0.05 divided by the number of CpGs taken forward from
discovery.
Sensitivity Models Adjusting EWAS Findings for Potential Confounding
by Genetic Variation
In order to demonstrate whether the DNA methylation and BMI association results were inde-
pendent of genetic variants influencing methylation (methylation quantitative trait loci
[meQTLs]), we conducted sensitivity models in the FHS for the replicated BMI-related CpGs
conditional on the top cis-meQTL (selected by lowest p-value; ±500 kb from the CpG) for each
replicated CpG. The approach to identify cis-meQTLs for the BMI-related CpGs is described
in S1 Methods.
Interindividual Variation in BMI and Distribution of Obesity in Relation to
EWAS Findings
In order to determine the magnitude of variation in BMI contained within the studied epige-
netic signatures in blood, we examined the variation captured in three ways. First, we exam-
ined the increase in model R2 starting from the baseline covariate-only linear regression
model, with BMI as the dependent variable, when adding nonredundant (|r|< 0.7) replicated
CpGs as independent variables in order of decreasing statistical significance. We conducted
this analysis in two discovery test sets: (1) methylome-wide significant CpGs in the FHS only
were tested in the LBCs and (2) replicated nonredundant CpGs from the BMI EWAS were
tested in one of the replication cohorts, PIVUS. Due to differences from the discovery cohorts
in ethnicity (African ancestry in ARIC) and cell line (CD4+ cells in GOLDN), we conducted
the variation analyses only in PIVUS. Second, we created an additive composite measure of
the same nonredundant statistically significant replicated CpGs weighted by effect size. The
composite methylation measure was generated for each individual by summing the product of
the methylation beta-value and the cohort-specific effect size (including direction of effect) for
each of the nonredundant replicated CpGs. The distribution of BMI and prevalence of obesity
(BMI 30 kg/m2) was assessed across deciles of the additive weighted composite measure in
the PIVUS cohort. Third, the change in BMI and odds of overweight (BMI 25–29.9 kg/m2)
and obesity were tested in age- and sex-adjusted linear and logistic regression models for each
standard deviation (SD) change in the additive weighted composite measure in the PIVUS
cohort. The weighted summation of the composite methylation measure was converted to SD
units (mean = 0, SD = 1) to enhance interpretability of results. As some of the cross-sectional
differential methylation changes were expected to be secondary to BMI differences, the pur-
pose of these analyses was not to develop a biomarker or risk predictor for cross-sectional BMI
measures but to determine if a large proportion of variation in BMI and obesity, and hence
obesity-related cardiometabolic risk, is reflected in the blood DNA methylation patterns. Fur-
ther analyses examine the molecular pathways that are affected and attempt to infer which
Methylome-Wide Study of BMI
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methylation changes are causally influencing BMI, which are secondary to BMI differences,
and which have relevance for clinical disease outcomes.
Gene Expression Analyses
We analyzed whole blood gene expression data in the FHS to identify which BMI-related dif-
ferentially methylated CpGs demonstrated association with altered gene expression. The repli-
cated CpGs were tested using linear mixed effects models for association, with the expression
level of the corresponding gene in whole blood (based on annotation by the manufacturer) as
the dependent variable and DNA methylation as the independent variable, adjusted for age,
sex, and technical and batch effects (further details in S1 Methods).
Functional and Regulatory Annotation
We studied the Gene Ontology (GO) biological process, molecular function, and cellular com-
ponent pathways (release 2016-08-22) of the genes identified in the BMI EWAS using the
PANTHER (protein annotation through evolutionary relationship) overrepresentation test
[23]. Secondarily, we restricted analysis to the higher certainty genes shown to have altered
whole blood gene expression in association with BMI-related differential methylation, as
described in the previous section. If multiple probes were annotated to the same gene, then the
gene was included only once (unweighted). As the methylation array covers 99% of RefSeq
genes, the background universe of genes tested was not restricted. Results were corrected for
multiple testing within each category.
In addition, we used eFORGE v1.2 (http://eforge.cs.ucl.ac.uk/) [24] to identify if the repli-
cated CpGs were enriched in DNase I hypersensitive sites (DHSs) (markers of active regulatory
regions) and loci with overlapping histone modifications (H3Kme1, H3Kme4, H3K9me3,
H3K27me3, and H3K36me3) across available cell lines and tissues from Roadmap Epige-
nomics Project, BLUEPRINT Epigenome, and ENCODE (Encyclopedia of DNA Elements)
consortia data [25–27].
Bidirectional and Two-Step Trans-tissue Mendelian Randomization
IV analyses using SNPs as IVs for (1) DNA methylation, (2) gene expression, and (3) BMI
were conducted in order to infer potential causal relationships between EWAS findings, BMI,
and adiposity-related diseases (the series of analyses conducted is outlined in Table 1). The
detailed approach is provided in S1 Methods. In brief, differences in methylation and expres-
sion were modeled using quantitative trait loci (QTLs), thus leveraging the contribution of
genetic variation to epigenetic traits to infer causal relations. Blood QTL IVs were selected as
the single top SNP methylation or expression association (by lowest p-value) in the FHS with
replication in the external cohorts or public datasets. As QTLs vary in effect in different tissue
types, we selected tissue-specific methylation and expression QTLs to examine tissue-specific
effects (details in S1 Methods). To model the effect of BMI on methylation (reverse causation),
the IV for BMI was assembled as an additive weighted genetic risk score from the 97 genome-
wide significant SNPs from the Genetic Investigation of ANthropometric Traits (GIANT) con-
sortium 2015 genome-wide association study (GWAS) results [7]. A sensitivity analysis utiliz-
ing a single SNP in the FTO (fat mass and obesity associated) locus as the IV for BMI was
conducted to examine an IV less prone to pleiotropy bias but also less powerful to detect
potential causal relations.
Forward MR, using the two-stage least squares method, tests the causal relation of differen-
tial methylation with BMI. SNP IVs that implicated a causal effect of differential methylation
on BMI from the forward MR (Bonferroni-corrected and, secondarily, nominal causal
Methylome-Wide Study of BMI
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p-value< 0.05) were tested in the trans-tissue two-step MR. The trans-tissue two-step MR was
implemented to further break down the relationship between DNA methylation and BMI and
to infer whether the hypothesized mediator (gene expression in multiple tissues) is influenced
by the exposure (DNA methylation) and, second, whether the mediator (gene expression in
multiple tissues) affects the outcome (BMI). SNP IVs that implicated a causal effect of differen-
tial methylation and expression on BMI were tested for associations with adiposity-related
phenotypes from published GWAS results. Finally, the reverse MR was conducted to test the
causal relation of BMI with downstream changes in DNA methylation.
Results
Discovery Cohort Characteristics
The discovery sample included 3,743 individuals: 2,377 from the FHS and 1,366 from the
LBCs (n = 446 from LBC1921 and n = 920 from LBC1936). The FHS, LBC1921, and
LBC1936 cohorts were older adults (mean [SD] age 67 [9], 79 [1], and 70 [1] y, respectively)
and had similar sex distribution (50%–60% female) and proportion of current smokers
(8%–11%) (Table 2).
Epigenome-Wide Association Study of BMI
Discovery. In the FHS-LBC EWAS meta-analysis, 135 CpGs were significantly associated
with BMI after correction for multiple testing in the primary age- and sex-adjusted model
(p< 1.2 × 10−7; full list and regression coefficients are provided in S1 Table; Q-Q plots in S1
and S2 Figs; Manhattan plot in S3 Fig; genomic inflation factor of discovery meta-analysis,
λ = 1.14). Similar results were observed following additional adjustment for smoking status
and after excluding 313 individuals with BMI outside of 18–35 kg/m2 (Models 2–3 in S2 Table;
S4 Fig).
External replication. The 135 statistically significant CpGs from the discovery BMI EWAS
meta-analysis (primary model) were tested for external replication in the ARIC (n = 2,096),
Table 1. Schema of instrumental variable analyses conducted in order to infer the potential causal relations between DNA methylation, gene
expression, BMI, and adiposity-related disease.
Method Exposure IV Source of IV Selection Outcome Setting
Forward MR DNA methylation meQTL FHS/replication
cohorts
All replicated CpGs
(as the exposure)
BMI FHS/GIANT consortium
Two-step MR—first step DNA methylation meQTL FHS/replication
cohorts
Significant in
forward MR
Gene expression in
multiple tissues
FHS/external eQTL datasets
from blood, liver, and adipose
tissue
Two-step MR—second
step
Gene expression in
multiple tissues
eQTL FHS/GTEx/
external eQTL
datasets
Significant in
forward MR
BMI FHS/GIANT consortium
Extension of causal
relations to adiposity-
related traits
DNA methylation meQTL FHS/replication
cohorts
Significant in
forward MR
Adiposity-related
traits
GWAS results
Gene expression in
multiple tissues
eQTL FHS/GTEx/
external eQTL
datasets
Significant in two-
step MR
Adiposity-related
traits
GWAS results
Reverse MR BMI BMI
GRS
GWAS results All replicated CpGs
(as the outcome)
DNA methylation FHS
BMI, body mass index; eQTL, expression quantitative trait locus; FHS, Framingham Heart Study; GIANT, Genetic Investigation of ANthropometric Traits;
GRS, genetic risk score; GTEx, Genotype-Tissue Expression Project; GWAS, genome-wide association study; IV, instrumental variable; meQTL,
methylation quantitative trait locus; MR, Mendelian randomization.
doi:10.1371/journal.pmed.1002215.t001
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GOLDN (n = 992), and PIVUS (n = 967) cohorts. There was external replication of 83 of 135
CpGs in at least one cohort (73 in ARIC, 22 in GOLDN, and 19 in PIVUS; S5 Fig) at p-
value< 3.7 × 10−4 (Bonferroni-corrected p-value for 135 tests), and 83 of 135 CpGs replicated
in the meta-analyses of the three replication cohorts and were taken forward for subsequent
analyses (S3 Table). Greater methylation was associated with higher BMI at 49 (59%) of the 83
replicated CpGs. The majority of BMI-related CpGs (65%–85% of CpGs depending on the
cohort) had mean sample CpG methylation levels between 20% and 80% (S4 Table). Fifty of the
83 replicated differentially methylated CpGs have not been previously reported in microarray-
based EWASs of BMI [28–36] (Table 3).
Age and sex interactions among the BMI EWAS findings. Among the 135 discovery
CpGs, a significant sex interaction was demonstrated in the discovery cohorts for one unanno-
tated CpG (cg26651978 on Chromosome 17q25.3; <3 kbp from the 30 end of LGALS3BP [lec-
tin galactoside-binding soluble 3-binding protein]), and a significant age interaction for one
CpG (cg24678869; DENND4B [DENN domain 4B Rab GDP-GTP exchange factor]) at p-
value < 3.7 × 10−4 (Bonferroni-corrected p-value for 135 tests) (S4 Table). The sex interaction
identified at cg26651978 (LGALS3BP) modestly replicated in the external cohorts (replication
meta-analyses p = 0.02), with larger regression coefficients and lower p-values in stratified
models among men than among women (replication meta-analyses p = 1.73 × 10−6 and 0.002
in men and women, respectively; overall and sex-stratified regression coefficients for each
cohort in S5 Table). The age interaction at cg24678869 (DENND4B) did not replicate in the
external cohorts (replication meta-analyses p = 0.9). Due to the narrow age range in PIVUS,
however, this interaction was tested only in ARIC and GOLDN (n = 3,079).
HIF3A locus methylation. Examining a previously identified BMI-related differential
methylation at the HIF3A locus [28], we demonstrated modest associations with BMI in the
FHS-LBC discovery cohorts for the three reported CpGs (p = 0.02 for cg22891070, p = 0.03 for
cg16672562, and p = 0.04 for cg27146050; no significant sex interactions). Stratifying models
at the median age of 66 y in the FHS (age range too narrow in LBC for stratification) revealed
stronger associations in the younger subset and null associations in the older subset (for
cg22891070, cg16672562, and cg27146050, p = 0.003, p = 0.008, and p = 0.046, respectively,
among participants66 y of age, and p = 0.9, p = 0.6, and p = 0.4, respectively, among partici-
pants>66 y of age).
Sensitivity models conditioning on cis methylation quantitative trait loci. Sensitivity
models conditioning on the top cis-meQTL (selected by lowest p-value; ±500 kb from the
CpG) in the FHS demonstrated minimal attenuation of the test statistic for the association of
BMI, with differential methylation at the majority of CpGs (81/83 [98%]) attenuated by less
than 20% (S6 Table).
Table 2. Study characteristics of the Framingham Heart Study and Lothian Birth Cohort participants (discovery cohorts) at the time of DNA meth-
ylation assays.
Characteristic FHS LBC1936 LBC1921
N 2,377 920 446
Age (years) 67 ± 9 70 ± 1 79 ± 1
Female 55% 40% 61%
BMI (kg/m2) 28.3 ± 5.4 27.8 ± 4.4 26.2 ± 4.0
Current smoking 8% 11% 7%
Data are counts, means ± standard deviation, and proportions as appropriate.
BMI, body mass index; FHS, Framingham Heart Study; LBC, Lothian Birth Cohort.
doi:10.1371/journal.pmed.1002215.t002
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Table 3. Fifty novel replicated differentially methylated CpGs associated with BMI sorted by p-value in the discovery cohorts.
CpG Gene Discovery Replication
FHS-LBC (n = 3,743) ARIC (n = 2,096) GOLDN (n = 992) PIVUS (n = 967) Meta-analysis
p-Value Dir p-Value Dir p-Value Dir p-Value Dir p-Value
cg17501210 RPS6KA2 4.14E−21 − − − − 1.72E−04 − 1.36E−06 − 4.15E−02 − 1.07E−06
cg14870271 LGALS3BP 4.87E−16 + + + + 2.28E−04 + 3.62E−03 + 4.80E−02 + 1.51E−05
cg11202345 LGALS3BP 6.22E−15 + + + + 7.70E−05 + 1.36E−02 + 1.83E−01 + 4.20E−05
cg19750657 UFM1 2.21E−13 + + + + 5.55E−06 + 6.92E−07 + 2.27E−08 + 5.60E−13
cg17901584 DHCR24 2.87E−12 − − − − 6.26E−07 − 1.23E−04 − 7.99E−07 − 4.14E−12
cg10179300 TRIO 5.71E−12 + + + + 7.37E−04 + 1.16E−02 + 8.82E−02 + 1.06E−04
cg10508317 SOCS3 2.90E−11 − − − − 1.31E−03 − 3.49E−05 − 2.85E−02 − 1.12E−05
cg17836612 LGALS3BP 1.05E−10 + + + + 4.73E−06 + 1.99E−03 + 7.40E−04 + 1.24E−08
cg26950531 DPF1 1.13E−10 − − − − 6.28E−04 − 6.49E−03 − 9.90E−04 − 2.22E−06
cg21429551 GARS 1.31E−10 − − − − 3.95E−03 − 1.13E−05 − 8.58E−02 − 6.76E−05
cg01881899 ABCG1 1.37E−10 + + + + 4.90E−03 + 4.99E−04 + 8.25E−02 + 1.98E−04
cg17782974 TRIM8 1.79E−10 + + + + 7.54E−06 + 5.71E−02 + 1.39E−01 + 1.05E−05
cg16611584 AKAP10 2.40E−10 + + + + 2.08E−04 + 9.92E−01 + 1.98E−02 + 1.40E−04
cg07730360 3.32E−10 + + + + 1.37E−06 + 3.31E−02 + 5.38E−02 + 8.00E−07
cg17738521 HIVEP2 3.51E−10 − − − − 2.36E−04 − 1.37E−01 − 7.56E−02 − 1.07E−04
cg18098839 GOLIM4 1.21E−09 − − − + 1.48E−03 − 1.12E−03 − 3.66E−04 − 1.42E−06
cg00108715 NT5DC2 1.71E−09 + + + + 1.98E−07 + 4.60E−01 + 4.00E−04 + 1.61E−08
cg24531955 LOXL2 2.26E−09 − − − − 3.85E−05 − 1.67E−02 − 9.20E−03 − 1.46E−06
cg17058475 CPT1A 2.28E−09 − − − − 3.18E−04 − 1.64E−05 − 1.29E−01 − 1.17E−05
cg24678869 DENND4B 2.56E−09 + + + + 4.72E−08 + 6.92E−01 − 4.46E−01 + 2.64E−05
cg13134297 3.21E−09 − − − − 1.10E−04 − 5.62E−03 − 2.06E−01 − 4.59E−05
cg10474597 SERPINE3 3.82E−09 + + + + 3.51E−04 + 2.13E−01 + 1.39E−04 + 2.19E−06
cg03725309 SARS 3.93E−09 − − − − 2.67E−04 − 2.75E−04 − 2.43E−03 − 6.00E−07
cg26894079 ASAM 4.06E−09 − − − − 2.31E−06 − 4.60E−05 − 1.96E−03 − 3.52E−09
cg22012981 ACOX2 4.65E−09 + + + + 2.64E−04 + 2.27E−02 + 1.97E−03 + 2.71E−06
cg26361535 ZC3H3 5.46E−09 − + + + 1.56E−07 + 2.65E−02 + 1.37E−02 + 3.43E−08
cg04286697 B3GNT7 5.96E−09 + + + + 8.70E−06 + 4.51E−02 + 7.53E−01 + 1.22E−04
cg26651978 6.24E−09 − − − − 6.42E−03 − 3.07E−04 − 2.76E−03 − 1.68E−05
cg19017142 7.86E−09 − − − − 1.48E−04 − 1.92E−02 − 1.80E−02 − 8.35E−06
cg10919522 C14orf43 9.71E−09 − − − − 3.98E−06 − 2.78E−04 − 8.58E−04 − 5.44E−09
cg25649826 USP22 1.05E−08 + + + + 9.69E−06 + 1.41E−03 + 6.62E−02 + 1.18E−06
cg07037944 DAPK2 1.19E−08 − − − − 2.47E−04 − 1.36E−01 − 4.12E−09 − 4.32E−09
cg24145109 1.23E−08 + + + + 2.69E−05 + 8.59E−02 + 2.28E−04 + 1.62E−07
cg01751802 KANK2 1.32E−08 + + + + 6.33E−07 + 8.89E−01 + 3.31E−01 + 4.30E−05
cg13274938 RARA 1.43E−08 + + + + 5.48E−07 + 3.47E−03 + 3.70E−02 + 9.57E−08
cg11673687 SLC9A1 2.52E−08 + + + + 7.80E−04 + 8.37E−01 − 7.96E−03 + 2.51E−04
cg26800893 ATPGD1 2.87E−08 − − − − 5.04E−04 − 8.10E−04 − 3.80E−04 − 4.29E−07
cg01368219 CACNA2D3 3.20E−08 + + + + 3.90E−06 + 2.21E−02 + 2.62E−02 + 6.87E−07
cg01130991 4.00E−08 + + + + 7.46E−06 + 2.49E−04 + 2.91E−02 + 2.19E−07
cg27470213 LGALS3BP 4.63E−08 − − − − 3.88E−05 − 1.23E−03 − 4.18E−03 − 2.64E−07
cg26955383 CALHM1 6.04E−08 + + + + 2.02E−04 + 3.52E−02 + 1.70E−01 + 1.15E−04
cg03500056 ABAT 6.19E−08 + + + + 4.21E−06 + 1.53E−02 + 8.29E−03 + 2.10E−07
cg09182678 6.22E−08 − − − − 1.03E−05 − 1.32E−03 − 5.88E−07 − 1.59E−10
cg02286155 6.39E−08 + + + + 2.99E−03 + 6.56E−03 + 7.40E−02 + 2.41E−04
cg12593793 7.12E−08 − − − − 1.59E−04 − 8.31E−03 − 2.04E−08 − 1.06E−09
(Continued )
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Interindividual Variation in BMI and Distribution of Obesity
The interindividual variation in BMI and distribution of obesity captured in the BMI EWAS
findings was evaluated. Regressing BMI on the 77 nonredundant (inter-probe correlation
|r|< 0.7) CpGs from the 83 replicated CpGs identified in the BMI EWAS revealed that 18% of
the interindividual variation (adjusted R2) in BMI is captured by differential methylation
beyond age and sex in the external replication cohort PIVUS (S6 Fig). This proportion is simi-
lar to that observed when examining a completely independent discovery test set using the 75
CpGs that were methylome-wide significant in the FHS discovery cohort (no replication),
which accounted for 17.5% of the interindividual variation in BMI (adjusted R2) beyond age
and sex in the LBCs. Creating an additive weighted composite measure of the 77 nonredun-
dant replicated CpGs and examining the distribution of BMI and obesity (BMI 30 kg/m2)
across deciles of the measure demonstrated that the median BMI increased in a graded manner
from 22 to 34 kg/m2 and the prevalence of obesity rose from 0% to 50% (Figs 2 and S7).
For each SD increase in the composite DNA methylation measure in the PIVUS replication
cohort, BMI increased by 1.63 (standard error 0.13) kg/m2 (p = 3.7 × 10−34). The odds ratios
for obesity (BMI 30 kg/m2) and overweight (BMI 25–29.9 kg/m2) compared to the reference
group (BMI< 25 kg/m2) were 2.8 (95% CI 2.3–3.5; p = 1.6 × 10−25) and 1.9 (95% CI 1.6–2.2;
p = 2.5 × 10−18), respectively, for each SD increase in methylation measure in age- and sex-
adjusted models.
Three-Way Association of DNA Methylation, Gene Expression, and BMI
We examined the association of DNA methylation at the 83 replicated BMI-related CpGs with
gene expression among 2,246 FHS participants, in order to determine which genes in blood
may be influenced by differential methylation of the BMI EWAS CpGs. Of the 83 replicated
CpGs, annotated gene expression from whole blood was available for 62 CpG–gene expression
pairs (three transcript results were unavailable on the microarray, and 18 CpGs were inter-
genic). There were significant associations (p-value< 8 × 10−4; 0.05/62) between differential
DNA methylation and gene expression in whole blood for 19 CpG–gene expression pairs,
representing ten unique gene transcripts (ABCG1,CPT1A, SREBF1, LGALS3BP, DHCR24,
PHGDH, SARS,NOD2, CACNA2D3, and SLC1A5), with almost all of the CpG–gene expression
pairs (18/19; 95%) demonstrating an inverse association of methylation with expression
Table 3. (Continued)
CpG Gene Discovery Replication
FHS-LBC (n = 3,743) ARIC (n = 2,096) GOLDN (n = 992) PIVUS (n = 967) Meta-analysis
p-Value Dir p-Value Dir p-Value Dir p-Value Dir p-Value
cg23172671 7.47E−08 + + + + 1.22E−04 + 7.70E−02 + 1.25E−01 + 8.01E−05
cg13139542 7.93E−08 − + + + 1.23E−05 + 1.05E−02 + 3.78E−01 + 2.67E−05
cg02571142 DKK4 9.91E−08 + + + + 6.33E−04 + 4.34E−03 + 6.97E−02 + 5.34E−05
cg21766592 SLC1A5 1.07E−07 − − − − 7.69E−03 − 5.41E−01 − 3.33E−04 − 1.34E−04
cg01526748 FGF12 1.18E−07 + + + + 5.32E−04 + 4.17E−04 + 3.32E−02 + 1.11E−05
The full list of the 83 replicated BMI-related differentially methylated CpGs is presented in S3 Table. The four directions of association with BMI for the
FHS-LBC cohorts indicate, in order, the two lab batches in the FHS and the LBC1936 and LBC1921 cohorts individually.
ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; Dir, direction of association with body mass index; FHS, Framingham Heart Study;
GOLDN, Genetics of Lipid Lowering Drugs and Diet Network; LBC, Lothian Birth Cohort; PIVUS, Prospective Investigation of the Vasculature in Uppsala
Seniors.
doi:10.1371/journal.pmed.1002215.t003
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(S7 Table). There were significant three-way associations (CpG versus BMI; CpG versus gene
expression; gene expression versus BMI) for 11 CpGs with seven unique annotated genes
(Table 4). Five of the seven genes (71%) with significant three-way associations between CpG–
gene expression–BMI are known to exhibit cardiometabolic phenotypes in murine gene
knockout models [37–44].
Functional and Regulatory Annotation of the BMI EWAS Findings
Gene Ontology pathway analyses. GO analyses of biological process, molecular function,
and cellular component pathways of the 55 unique genes annotated to the 83 replicated CpGs
(ten CpGs were annotated to genes annotated to other replicated CpGs, and 18 CpGs were
intergenic) did not identify any statistically significant pathways after adjustment for multiple
testing. Secondarily, in order to further refine gene selection for GO analyses to the genes that
demonstrated altered expression, we restricted the GO analyses to the ten unique genes for
which variation in expression was associated with differential methylation, as described in the
previous section. We identified significant overrepresentation of a biological process pathway
Fig 2. Histogram of the proportion of obese individuals (BMI 30 kg/m2) in the PIVUS cohort across deciles of the
additive weighted composite methylation measure of the 77 nonredundant replicated CpGs (|r| < 0.7) from the BMI
epigenome-wide association study. BMI, body mass index; PIVUS, Prospective Investigation of the Vasculature in
Uppsala Seniors.
doi:10.1371/journal.pmed.1002215.g002
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in the positive regulation of lipid metabolic processes (GO:0045834; adjusted p-value = 0.002;
64-fold enrichment; four overlapping genes [ABCG1, SREBF1,CPT1A and NOD2] of 130 total
genes in pathway) and two related processes (positive regulation of the cholesterol biosynthetic
[GO:0045542] and cholesterol metabolic [GO:0090205] processes; adjusted p-value = 0.02–
0.03).
Regulatory annotation of CpGs associated with gene expression in blood. Most BMI-
related CpGs associated with altered gene expression were located within 50 kb of the transcrip-
tion start site and were within known enhancer or DHSs (S8 and S9 Figs). CpGs associated with
BMI were more likely to be in enhancers and DHSs (enrichment p-value = 4.5 × 10−7 and
9.4 × 10−4, respectively) and less likely to reside in CpG islands (depletion p-value = 3.2 × 10−11)
compared to the full set of measured CpGs on the microarray (S8 Table).
DNase I hypersensitive site testing of all identified CpGs. Tissue- and cell-type-specific
DHS enrichment testing using the eFORGE v1.2 tool demonstrated that the BMI-related
CpGs are enriched in DHSs across almost every tissue and cell type assayed in the included
ENCODE, BLUEPRINT Epigenome, and Roadmap Epigenomics Project datasets (S10 and
S11 Figs), thus supporting the notion that the CpGs identified in blood are also situated in
known active regulatory regions in not only blood, but also other metabolically active tissues.
Table 4. Association results from 11 replicated CpGs with significant three-way associations in whole blood between CpG methylation and BMI,
CpG methylation and gene expression, and gene expression and BMI.
Gene (GEx
Probe Number)
CpG CpG versus
BMI
CpG versus GEx GEx versus BMI Protein Function and Transgenic Mouse
Cardiometabolic Phenotype
Dir p-Value Dir R2 p-Value Dir R2 p-Value
ABCG1
(#3922444)
cg06500161 + 7.6 × 10−43 − 0.112 1.2 × 10−59 − 0.023 6.2 × 10−73 Function: membrane transporter for cholesterol
and phospholipids; transgenic mouse: decreased
susceptibility to diet-induced obesity, smaller
adipocytes, lower weight [37]
cg27243685 + 2.3 × 10−15 − 0.054 4.4 × 10−29 − 0.023 6.2 × 10−73
cg01881899 + 1.4 × 10−10 − 0.035 3.8 × 10−19 − 0.023 6.2 × 10−73
cg10192877 + 1.7 × 10−08 − 0.014 1.7 × 10−08 − 0.023 6.2 × 10−73
CACNA2D3
(#2624639)
cg01368219 − 3.2 × 10−08 − 0.014 2.9 × 10−08 − 0.006 1.1 × 10−08 Function: voltage-dependent calcium channel
complex; transgenic mouse: decreased serum free
fatty acids [38]
CPT1A
(#3379644)
cg00574958 − 2.2 × 10−29 − 0.025 7.7 × 10−14 + 0.017 4.5 × 10−24 Function: transporter across the mitochondrial
inner membrane for fatty acid beta oxidation;
transgenic mouse: decreased serum glucose and
increased serum free fatty acid levels after fasting
[39]
cg17058475 − 2.3 × 10−09 − 0.014 2.2 × 10−08 + 0.017 4.5 × 10−24
DHCR24
(#2413907)
cg17901584 − 2.9 × 10−12 − 0.017 8.9 × 10−10 + 0.003 1.4 × 10−07 Function: catalyzes the reduction of sterol
intermediates during cholesterol biosynthesis;
transgenic mouse: decreased subcutaneous and
mesenteric adipose stores, decreased body size,
decreased circulating cholesterol [40]
SARS
(#2350551)
cg03725309 − 3.9 × 10−09 − 0.011 6.6 × 10−07 + 0.011 4.7 × 10−10 Function: catalyzes the transfer of L-serine to
tRNA; transgenic mouse: no cardiometabolic
phenotypes reported
SLC1A5
(#3866276)
cg02711608 + 6.3 × 10−08 − 0.013 5.1 × 10−08 + 0.023 1.7 × 10−69 Function: amino acid transporter; transgenic
mouse: no cardiometabolic phenotypes reported
SREBF1
(#3747966)
cg11024682 + 4.8 × 10−22 − 0.009 8.0 × 10−06 − 0.003 5.2 × 10−05 Function: transcription factor for sterol
biosynthesis; transgenic mouse: abnormal fat cell
and fat pad morphology, abnormal lipid
homeostasis, insulin resistance, enlarged liver [41–
44]
Complete list of results for all methylome-wide significant CpGs is available in S8 Table.
BMI, body mass index; Dir, direction of correlation; GEx, gene expression.
doi:10.1371/journal.pmed.1002215.t004
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Further stratification by whether BMI-related CpGs had overlapping H3 histone methylation
revealed that the BMI-related CpGs predominately overlapped regions with mono-methyla-
tion and, to a lesser extent, tri-methylation of lysine 4 on histone H3K4 (H3K4me1 and
H3K4me3) across numerous tissues from the consolidated Roadmap Epigenomics Project
data (S12–S14 Figs). H3K4me1 marks are indicative of enhancers, H3K4me3 marks are indica-
tive of promoters, and both are known markers of transcriptional activation.
Genetic Instrumental Variable Analyses (Mendelian Randomization)
Successive genetic IV analyses were conducted to infer causal relations between differential
methylation, gene expression, and BMI, followed by evaluation of the modeled epigenetic
changes on adiposity-related traits using GWAS results (Table 1).
Forward Mendelian randomization. Testing the causal association of DNA methylation
with BMI revealed that differential methylation at two CpGs had nominally significant
causal associations (p-value< 0.05) with BMI: (1) cg11024682 (SREBF1; cis-meQTL SNP IV
rs752579) and (2) cg07730360 (a non-annotated CpG on Chromosome 3q21.3; trans-meQTL
SNP IV rs13437553), with causal p-value = 0.02 and 0.04, respectively (S15 Fig; S9 Table). Tak-
ing forward the two causal CpGs in discovery for external validation, we found that modeled
differential methylation at one of the two CpGs (cis-meQTL SNP IV rs752579 for differential
methylation at cg11024682 [SREBF1]) was associated with BMI in the 2015 GIANT consor-
tium results (p = 0.0003; all ancestries).
Two-step Mendelian randomization (first step). In the first step (DNA methylation
affecting the mediator, gene expression), the SNP IV (rs752579) utilized in the forward MR
analyses to model differential methylation of the SREBF1 locus (cg11024682) was also found to
be strongly associated with altered SREBF1 gene expression in blood in the FHS (p = 3 × 10−12;
decreased expression in relation to the C allele), a published [45] blood expression quantitative
trait locus (eQTL) dataset (p = 3.2 × 10−6; direction of effect in blood consistent with that seen
in the FHS), and liver (p = 1 × 10−15; in the same direction as observed in blood in a reanalysis
of 958 samples [46,47]).
Two-step Mendelian randomization (second step). In the second step (gene expression
in blood and alternate tissues affecting BMI), we identified adequate eQTLs for SREBF1
expression in whole blood (rs1889018; p = 1.7 × 10−15) from the FHS; in adrenal gland
(rs4925138; p = 1.1 × 10−6) and liver (rs11078366; p = 1.8 × 10−6) from the Genotype-Tissue
Expression (GTEx) Project; and in adipose tissue (rs4985779; p = 8.4 × 10−4) from the larger
MuTHER dataset [48]. The multi-tissue SREBF1 eQTLs were selected to be largely indepen-
dent from the SREBF1 methylation locus SNP IV (details in S1 Methods). We identified signif-
icant associations with BMI (adjusted for the four tests, p< 0.013) in the GIANT consortium
results for two of the four tissue types; specifically, BMI was associated with the SNP IV for
SREBF1 expression in whole blood (rs1889018, p = 0.002) and adrenal gland (rs4925138, p =
0.0098), but not liver (rs11078366, p = 0.89) or adipose tissue (rs4985779, p = 0.80).
Adiposity-related traits in GWASs. Assessing other cardiometabolic disease associations
from published GWASs, the SNP IV (rs752579) for exposure to differential methylation at the
SREBF1 locus (cg11024682) was also found to be associated with (1) adiposity-related traits
[49–51] (waist-hip ratio adjusted for BMI [p = 2.0 × 10−4], adiponectin [p = 0.007], birthweight
[p = 0.046]), (2) diabetes traits [52–55] (type 2 diabetes [p = 0.002], fasting insulin adjusted for
BMI [p = 0.001], HbA1C [p = 0.003], HOMA-B [p = 0.007]), (3) lipid levels [56] (triglycerides
[p = 0.001], high-density lipoprotein cholesterol [p = 0.03]), and (4) coronary artery disease
[57] (p = 1.7 × 10−6). Additionally, the SNP IV for increased SREBF1 expression in whole blood
(rs1889018) was also associated with waist-hip ratio (p = 0.0002), adiponectin (p = 0.003), and
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triglycerides (p = 0.02) based on GWAS results [49,50,56]. The SNP IV for increased SREBF1
expression in the adrenal gland (rs4925138) was also nominally associated with adiponectin
(p = 0.02), triglycerides (p = 0.022), and low-density lipoprotein change in response to statin
treatment (p = 0.04) [50,56,58].
Causal effect estimates. Each SD increase in DNA methylation at the SREBF1 locus
(cg11024682) was predicted to result in a 2.8-kg/m2 decrease in BMI in the FHS (modeling the
effect of allele C for rs752579). In contrast, the observed relationship between methylation in
blood and BMI in the FHS was in the opposite direction: a 1.0-kg/m2 increase in BMI per SD
increase in DNA methylation at cg11024682. The predicted direction of effect between methyl-
ation and BMI is partly derived from the observed direction of effect between the SNP IV and
methylation in blood. Previous literature has reported cell-type-dependent QTLs with opposite
directions of effect between a SNP and methylation or expression depending on the cell or tis-
sue type examined [59]. As extensive databases of trans-tissue methylation are unavailable, we
examined trans-tissue eQTLs for SREBF1 from the GTEx Portal [60]. A series of eQTLs for
SREBF1 (false discovery rate 0.05) demonstrate opposite direction of effect between blood
versus adrenal gland (p-value< 10−6) and additional tissues (at p-value< 10−5) such as
skeletal muscle, esophagus, aorta tissue, and tibial nerve (http://www.gtexportal.org/home/
bubbleHeatmapPage/SREBF1). Strong eQTLs for SREBF1 are likely present in adrenal tissue
as SREBF1 is highly expressed in the adrenal gland compared to other tissues (http://www.
proteinatlas.org/ENSG00000072310-SREBF1/tissue). For example, rs854764 is a strong eQTL
for SREBF1 in both blood and adrenal tissue but in opposite directions (p = 3.8 × 10−12 and
p = 4 × 10−6, respectively, in the GTEx catalog) and is associated with BMI in GIANT (p =
0.001) and waist-hip ratio (p = 9.2 × 10−4), adiponectin (p = 0.02), HbA1C (p = 0.02), type 2
diabetes (p = 0.03), triglycerides (p = 0.04), and coronary artery disease (p = 1.1 × 10−5) in
GWAS results [4,7,50,52,54,57,61]. This SNP, rs854764, is also a meQTL for SREBF1 locus
methylation at cg11024682 in the FHS (p = 2.8 × 10−18), but the association with SREBF1 locus
methylation in adrenal gland, the potential tissue of effect, is unknown. See S10 Table for
causal effect estimates and confidence intervals for the second step of the two-step MR
analyses.
Reverse Mendelian randomization. To test whether BMI affects methylation at the iden-
tified CpGs, the additive weighted genetic risk score of 97 known BMI SNPs [7] was used as an
IV for BMI (F-test statistic = 26). Sixteen CpGs were found to be differentially methylated as a
consequence of BMI using a nominal causal p-value< 0.05 cutoff (full list in S11 Table). The
16 downstream CpGs were annotated to 12 genes (ABCG1,USP22, DPF1, RARA,KDM2B,
KANK2, RALB,NT5DC2,DENND4B,B3GNT7,DKK4, and ABAT). A sensitivity analysis using
a single SNP in the FTO locus as a BMI IV (S12 Table) further supported causal associations
downstream of BMI at two of the 16 CpGs (nominal causal p-value< 0.05 for cg06500161 and
cg04286697, at the ABCG1 and B3GNT7 loci, respectively). The annotated genes with BMI-
related differential methylation are characterized in Fig 3.
Discussion
In this analysis of the association of BMI with differential methylation of blood-derived DNA,
we provide robust evidence of a connection between replicable epigenetic signaling at 83 CpGs
and BMI. We also demonstrate the correlation of BMI-related differential methylation with
the altered expression of ten genes in whole blood that are overrepresented in lipid metabolism
pathways. Among the 83 replicated BMI-related CpGs, one differentially methylated locus
(cg11024682) at the lipid metabolism transcription factor SREBF1 demonstrated evidence of a
causal effect on BMI; genetically predicted exposure to differential methylation and expression
Methylome-Wide Study of BMI
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of SREBF1was found to be associated with BMI and other adiposity traits, glycemic traits, dys-
lipidemia, and coronary artery disease. In contrast, we found that a substantial proportion (16
out of 83 [19%]) of the BMI-related differentially methylated CpGs identified in this EWAS
are likely a consequence of BMI (i.e., downstream signals).
BMI Variation Is Reflected in DNA Methylation Signatures in Blood
A substantial proportion (~18%) of interindividual variation in BMI is captured by the repli-
cated differentially methylated CpGs in blood. The magnitude of BMI difference (~12 kg/m2
between the highest and lowest deciles) equates to substantial health risks; for example, each
5-kg/m2 increase in BMI in the general population is associated with a 30% increase in mortal-
ity [62].
Fig 3. Annotated genes of replicated differentially methylated CpGs identified in the BMI epigenome-wide association study.
Genes are grouped by association with gene expression, association of gene expression with BMI, and Mendelian randomization analyses
for causal support. Duplicate gene names within the same group are not shown. Figure does not include 18 intergenic CpGs without a gene
annotation. BMI, body mass index; EWAS, epigenome-wide association study.
doi:10.1371/journal.pmed.1002215.g003
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Our results suggest that epigenetic biomarkers hold the potential to improve risk prediction
and help tailor therapy choices to prevent or treat cardiometabolic diseases. For example, at
the population level, BMI is an effective measure of average future cardiometabolic disease risk
[63], but it is insufficiently predictive at the individual level. Regardless of causality, blood-
based biomarkers can be useful for prognostic or diagnostic purposes. Further research is
required to determine whether refining BMI-related risk by incorporating epigenetic biomark-
ers can improve risk prediction and help guide treatment decisions.
Differential Methylation Is Identified in Loci Known to Be Involved in
Adiposity
Lipid metabolism. Previously conducted experiments support a causal role of SREBF1 in
adiposity [64]. SREBF1 (also known as SREBP1) plays a central role in energy homeostasis by
promoting glycolysis, lipogenesis, and adipogenesis via induction of the conversion of acetyl-
CoA to triglycerides (S16 Fig). SREBF1 promotes the conversion of free fatty acids to triglycer-
ides in the liver and to triglyceride-rich lipoproteins in the bloodstream. In situations of caloric
excess, SREBF1 is a key mediator of the induction of lipogenesis in humans [64]. In mice with
diet-induced insulin resistance, inhibition of SREBF1 attenuates accelerated atherosclerosis,
supporting a link to atherosclerosis and coronary artery disease [65]. The causal connection
between increased triglyceride-rich lipoproteins and coronary disease is supported by human
genetic studies [66]. We highlight the potential role of SREBF1 expression in the adrenal gland
in weight regulation and adiposity-related diseases based on results from the MR analyses. Dis-
eases of the adrenal gland are known to be linked to severe obesity, and adrenalectomy in
murine models can reverse genetically induced obesity [67,68]. Our results suggest that altered
genomic regulation of SREBF1 is causally related to BMI; however, the lack of large datasets of
meQTLs in numerous tissues and under various conditions, in combination with the inability
to conduct tissue-targeted epigenetic editing in relevant experimental models, limits our ability
to make a definitive causal inference. Regulation of SREBF1 is an underexplored target for the
prevention of coronary artery disease.
Another of our top genes, CPT1A (carnitine palmitoyltransferase 1A), is an outer mito-
chondrial membrane enzyme involved in the utilization of acetyl-CoA, functioning as a key
enzyme in the beta-oxidation of long-chain fatty acids in mitochondrial energy metabolism.
Acetyl-CoA has recently been identified as a central link between altered lipolysis due to adi-
posity or inflammation and resultant changes in hepatic insulin resistance with cross-com-
munication between liver and adipose tissue [69]. ABCG1 (ATP binding cassette G1), a cell-
membrane lipid transporter, has an established role in reverse cholesterol transport; its role
in obesity is supported in previous animal [37] and human studies [70]. DHCR24 (24-dehy-
drocholesterol reductase) catalyzes the reduction of sterol intermediates during cholesterol
synthesis. Differential methylation of SREBF1, CPT1A, ABCG1, and DHCR24 has been
reported in previous EWASs of adiposity, glycemic traits, and lipids [29–31,71–76]. We add
to the published literature and provide evidence that differential methylation at the ABCG1
locus is likely a downstream effect of BMI. From these findings taken together, epigenetic
dysregulation is emerging as a common link between obesity and obesity-related comorbidi-
ties. Although further functional research is required, we hypothesize that obesity and adi-
posity-related diseases are partly driven by changes in DNA methylation, with resultant
dysregulation of energy balance via effects on expression of lipid metabolism pathway genes.
Regulatory mechanisms involved in energy homeostasis have been proposed as attractive tar-
gets for the treatment of obesity, metabolic syndrome, and heart disease [77,78]. Our results
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demonstrate that these connections are evident in humans, adding to previous evidence
from animal models [78].
Inflammatory pathways. Aside from the lipid metabolism genes, a number of loci
involved in inflammatory pathways were identified by our EWAS. Enlarged adipocytes in
obese individuals are known to promote inflammation. One BMI-related differentially meth-
ylated CpG was identified at the NOD2 (nucleotide binding oligomerization domain 2) locus.
NOD2, an innate immune receptor, is involved in the immune response to bacterial lipopoly-
saccharides (LPSs) by activating NF-κB signaling. Uptake of LPS from gut microbiota has
been demonstrated to result in increased internalization of LPS-rich lipoproteins into adipo-
cytes and promote macrophage conversion from the M2 form to the inflammatory M1 form
[79]. NOD2 is also included in the GO pathway for regulation of lipid metabolism (0045834)
as it is a positive regulator of phosphatidylinositol 3-kinase activity and has been demon-
strated to promote vascular inflammation and formation of lipid-rich atherosclerotic lesions
in hypercholesterolemic LDLR−/− mice [80,81]. NOD2 interacts with another BMI-related
differentially methylated inflammatory gene locus at SOCS3 (suppressor of cytokine signaling
3), a negative regulator of cytokine signaling. In addition, LGALS3BP (lectin, galactoside
binding soluble 3 binding protein), also known as MAC2BP (Mac-2-binding protein), is
involved in the immune response associated with lymphokine-activated killer cell cytotoxic-
ity and platelet activation, signaling, and aggregation. LGALS3BP has been found to stimulate
host defenses and is elevated in individuals with various types of cancer such as breast, lung,
colorectal, ovary, and endometrial cancers, many of which are obesity-related. In addition,
LGALS3BP was recently identified as a promising biomarker for non-alcoholic steatohepati-
tis and pancreatitis [82,83], known obesity-related diseases. Methylation at the LGALS3BP
locus demonstrated a significant sex interaction, with a stronger effect in men. This may be
related to environmental factors more common in men (such as specific dietary patterns) or
male-specific physiology.
Differential Methylation Is Identified in Loci Not Previously Linked to
Adiposity
Serine metabolism. Two of the ten genes differentially expressed in association with
BMI-related methylation (PHGDH and SARS) are involved in L-serine metabolism. PHGDH
(phosphoglycerate dehydrogenase) is involved in the early steps of the synthesis of the amino
acid L-serine, which plays a role in oxidoreductase as a NADP acceptor in the tricarboxylic
acid cycle. SARS (seryl-TRNA synthetase) catalyzes the transfer of L-serine to tRNA. In addi-
tion, RPS6KA2 (ribosomal protein S6 kinase A2), a locus not previously reported as being BMI-
related, is a serine/threonine kinase that acts downstream of MAPK signaling and is involved
in cell proliferation. L-serine is necessary for specific functions in the central nervous system;
however, the link between adiposity and functional health consequences via effects on serine
metabolism is currently unknown.
Cell-membrane transporters. In addition to the cell-membrane transporters discussed,
two additional membrane transporters were identified among the ten genes associated with dif-
ferential methylation. SLC1A5 (solute carrier family 1 member 5), which was found to have sig-
nificant three way associations with altered gene expression in blood and BMI, is a sodium-
dependent transporter of amino acids. It is activated by insulin concentration, which is often ele-
vated in individuals with obesity. BMI-related differential methylation was also identified at the
CACNA2D3 (calcium channel, voltage-dependent, alpha 2/delta subunit 3) locus. CACNA2D3 is
involved in nerve signal transmission and cardiac conduction.
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BMI EWAS Findings in the Context of Published Epigenetic
Epidemiology Studies
Previous in silico methods of identifying putative epigenetically regulated obesity genes
highlighted SOCS3 (suppressor of cytokine signaling 3) and RARA (retinoic acid receptor alpha)
[84], both of which were identified in the FHS-LBC meta-analysis (p = 2.7 × 10−11 for
cg27637521 in SOCS3 and p = 1.3 × 10−8 for cg13274938 in RARA). An association study of
DNA methylation and BMI in 459 individuals from the Cardiogenics Consortium identified
an association of methylation at three CpGs intronic to HIF3A (hypoxia inducible factor 3A) in
blood and adipose cells with BMI [28]. We found modest associations of differential methyla-
tion and expression at the HIF3A locus with BMI in our study. However, the associations were
stronger in younger individuals in the FHS, suggesting that the connection may be less appar-
ent at older ages.
At a nominal causal p-value< 0.05, we found that many (16 [19%]) of the replicated CpGs
are downstream of BMI. This is consistent with recent findings from longitudinal methylation
data and bidirectional MR in the Avon Longitudinal Study of Parents and Children [85] that
BMI-related HIF3A methylation is likely secondary to differences in BMI.
There is substantial overlap between the identified BMI-related CpGs and reported CpG–
metabolite associations in blood from 1,814 participants in the KORA cohort (Kooperative
Gesundheitsforschung in der Region Augsburg) [86] (S13 Table). Notably, ceramides and
sphingolipids—known to have altered levels among obese individuals and implicated in the
development of the metabolic syndrome [87–89]—were identified. In addition, the BMI-
related differentially methylated CpG (cg03725309) at the SARS locus, as discussed above in
the serine metabolism section, was found to be associated with blood levels of serine.
BMI EWAS Findings in the Context of BMI GWAS Results and Nearby
Genetic Variants
Of note, none of the CpGs associated with BMI was near genes previously identified in
GWASs of obesity-related traits, such as FTO (fat mass and obesity associated) or MC4R (mela-
nocortin 4 receptor). We hypothesize that many of the replicated differentially methylated loci
reflect novel pathways involved in the regulation of adiposity or adiposity-related diseases.
Long-range interactions of DNA methylation with known obesity-related loci, however, may
exist [90]. Further work to understand the role of the novel loci in relation to adiposity is also
required. In addition, combining information from DNA methylation with genetic markers
identified from DNA sequence variation may allow for improvements in risk prediction previ-
ously not possible with sequence variants alone [91].
Many of the significant loci from the discovery phase (73 of 135) were replicated in Afri-
can-Americans from the ARIC study [30]. Similarly, many of the BMI-related differentially
methylated CpGs identified in this study were also reported in relation to BMI in people of
Arabic ancestry [34]. In GWASs, failure to replicate across racial/ethnic groups may be due to
differences in allele frequencies and linkage disequilibrium patterns. In contrast, the high rate
of replication of DNA methylation results for BMI in individuals of European and African and
other ancestries suggests that shared environmental exposures or changes secondary to differ-
ences in BMI, and not genetic variation, may underlie many of the associations. Further work
is needed to identify environmental factors that promote or mitigate disease-relevant obesity-
related epigenetic dysregulation. Our analyses that conditioned on top meQTLs showed mini-
mal attenuation, suggesting that the association between differential methylation and BMI is
largely independent of genetic variants near the reported CpGs.
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Study Limitations
Our study has several limitations. Results from MR analyses utilizing genetically predicted
methylation and expression levels do not prove causation but provide supportive evidence.
The results of the MR analyses are based on numerous assumptions, for example, that there
are not alternative pathways through which the SNP IV may act on BMI (i.e., pleiotropic
effects). The MR assumptions cannot be tested directly and may bias the results. The forward
MR results did not reach Bonferroni-adjusted significance thresholds for multiple testing;
however, validation of the nominally significant results in the larger GIANT consortium sup-
ports our findings. We avoided the use of multi-SNP score IVs as we had already identified
adequate single SNP meQTLs and using multi-SNP score IVs would have further risked intro-
ducing bias due to pleiotropy. The meQTLs for the MR analyses were derived in the FHS and
the outcome was tested within the same cohort, which can potentially result in bias toward
significance. The MR analyses, using the blood meQTL IV, suggest an inverse relationship
between the predicted methylation of the SREBF1 locus and BMI, the reverse of the observed
relationship, which can be interpreted as a null result. This finding is potentially explained by
different directions of effect of QTLs in alternate tissues, which was supported by examining
the association of genetic variants in blood versus other metabolically active tissues in the
GTEx Project resource. Unfortunately, there are limited datasets of meQTLs in various tissues
to explore this further. The observation of associations of BMI with methylation at the same
CpG in different directions of effect in blood versus adipose-derived DNA has been previously
reported at BMI-related CpG sites [30]. For SREBF1, we presume that the metabolic conse-
quences of altered methylation and the effect on BMI occur in tissues other than blood, such
as the adrenal gland, with the methylation changes in blood that we were able to detect repre-
senting a biomarker of trans-tissue differential methylation [92]. In addition, it is possible that
positive and negative feedback loops can result in regulation of the same gene to be both a
causal and a downstream effect of adiposity. We would not be able to discern this scenario
from the observational cross-sectional data in this study.
An alternate methylation assay would be required for clinical purposes as the current
microarrays are unsuitable in a clinical setting. Future research would be required for technical
validation for clinical purposes. Our study supports blood cells as a useful accessible tissue for
epigenetic biomarker discovery in large population studies. However, our study would not be
able to detect tissue-specific methylation changes occurring in non-blood cell lines (e.g., neu-
ron-specific epigenetic modifications in relation to BMI). Many of our top CpGs replicated in
the GOLDN study, which assessed DNA methylation in a single blood cell type (CD4+), sug-
gesting that the associations we detected are not likely to be due to confounding by blood cell
heterogeneity. Many of the genes associated with BMI-related differential methylation were
known to have a role in adiposity and cardiometabolic traits from murine knockout models;
however, the universe of knockout models is likely enriched for the study of adiposity and car-
diometabolic traits, and we could not directly test whether our results identified more than
expected. Our study was conducted among older-age adults, and the findings may not be gen-
eralizable to younger ages.
Conclusions
We provide the results of a large EWAS of BMI in almost 8,000 individuals that identified 83
replicable DNA methylation loci and evidence of complementary transcriptomic differences
that were enriched for gene products involved in lipid metabolism. The genetic IV analyses
prioritize the SREBF1 locus for future functional studies to further define the causal relation
with adiposity, insulin resistance, obesity-related dyslipidemia, and coronary artery disease.
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Our findings provide a foundation for further research to determine if individualized epige-
netic profiles can be used to guide clinical decision making and improve health outcomes. Our
findings may have additional clinical and therapeutic relevance if other loci that are differen-
tially methylated in relation to BMI represent attractive targets for the treatment or prevention
of obesity and adiposity-related diseases.
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